Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) has announced its first commercial sales of the next-generation Swoop® Portable MR Imaging system, powered by Optive AI™ software. Two leading hospitals in the northeastern United States have purchased the units following recent FDA clearance, planning to deploy them in intensive care units and emergency departments.
The new Swoop® system features enhanced signal-to-noise ratio and, combined with Optive AI™ software, delivers improved image resolution, uniformity, and faster acquisition times. The system's patient-centric design makes it particularly suitable for pediatric, elderly, and anxious patients, advancing Hyperfine's mission to transform MRI accessibility.
Hyperfine (NASDAQ: HYPR) has received FDA clearance for its Optive AI™ software, a significant upgrade for its Swoop® system - the world's first FDA-cleared AI-powered portable MRI system for brain imaging. The tenth-generation software release delivers substantial improvements in image quality through enhanced AI algorithms that optimize noise cancellation, image acquisition, reconstruction, and post-processing.
Early clinical users reported image quality approaching that of conventional 1.5 tesla MRI scanners. The company plans to roll out the software to accounts in Q3 2025. This release represents one of two major technology milestones for 2025, supporting Hyperfine's growth strategy for expansion into new hospital sites and entry into the neurology office market.
Hyperfine (NASDAQ: HYPR), known for developing the Swoop® system - the first FDA-cleared AI-powered portable magnetic resonance brain imaging system, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5th at 4:20pm ET and will be available for in-person meetings on Wednesday, June 4th. Interested parties can schedule one-on-one meetings through their Jefferies representative.
Hyperfine (Nasdaq: HYPR), creator of the pioneering Swoop® system - the first FDA-cleared portable magnetic resonance brain imaging system - has scheduled its Q1 2025 financial results announcement for May 13, 2025.
Key Details:
- Event Date: Tuesday, May 13, 2025
- Conference Call Time: 1:30 PM Pacific / 4:30 PM Eastern
- Access: Live audio webcast available through Hyperfine's investor relations website
- Registration: Participants should register at least 15 minutes before the call
The webcast recording will be archived and accessible through the company's investor portal at https://investors.hyperfine.io/
Hyperfine (NASDAQ: HYPR) has initiated the NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study, enrolling initial patients to evaluate their AI-powered portable MRI system in neurology offices. This multi-center study compares their Swoop® system, first FDA-cleared in 2021, with conventional high-field MRI systems.
The study, conducted at the DENT Neurologic Institute and Texas Neurology, targets 100 patients and aims to conclude by year-end. It will assess pathology findings, clinical utility, and patient experience. The portable system offers significant advantages, requiring no costly siting, helium, or specialized MRI technologists.
Notably, starting November 2024, IAC Accredited medical offices using portable MRI systems will qualify for Centers for Medicare and Medicaid Services (CMS) reimbursement, potentially expanding accessibility in underserved, rural, and community centers.
Hyperfine (HYPR) reported Q4 2024 financial results, with revenues of $2.32 million, down from $2.69 million in Q4 2023. The company sold 9 Swoop® systems in Q4 2024 versus 7 in Q4 2023.
Full year 2024 revenues increased 17% to $12.89 million, with 48 Swoop® systems sold compared to 37 in 2023. Gross margin improved to 46% from 43%. Net loss for 2024 was $40.72 million ($0.56 per share), improved from $44.24 million ($0.62 per share) in 2023.
The company strengthened its financial position through a $6.0 million registered direct offering, extending cash runway through 2026. For 2025, management projects revenue growth of 20-30% and reduced cash burn of $25-27 million, a 32% decline from 2024.
Hyperfine (Nasdaq: HYPR) has announced a strategic collaboration with NVIDIA to enhance its AI-powered portable MRI technology. The partnership focuses on advancing the Swoop® system, the first FDA-cleared AI-powered portable magnetic resonance brain imaging system.
The collaboration aims to leverage NVIDIA's AI expertise and accelerated computing to make brain MRI faster, smarter, and more affordable globally. Using NVIDIA's advanced suite of training and inference tools, including NVIDIA DALI and MONAI, the partnership will work on improving image quality, reducing scan times, and enabling faster diagnoses.
This initiative addresses a critical healthcare gap, as 90% of the global population lacks access to timely MRI diagnostics due to conventional MRI systems' high costs and infrastructure requirements. The Swoop® system is designed for point-of-care use in professional healthcare settings by trained clinicians, targeting the over three billion people worldwide affected by brain diseases.